Evidence map›Paper›PMID 30474955›Full record

ArticleACS chemical neuroscience2019

Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models.

Kristopher K Abney, Michael Bubser, Yu Du, Krystian A Kozek, Thomas M Bridges, Craig W Linsdley, J Scott Daniels, Ryan D Morrison, Kevin Wickman, Corey R Hopkins and 2 more

Erratum issuedAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. GABAJournal of neurochemistry · 2025
    Article
  4. Neuronal G protein-gated KAmerican journal of physiology. Cell physiology · 2022
    Review
  5. AsKC11, a Kunitz Peptide fromMarine drugs · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Advances in Targeting GIRK Channels in Disease.Trends in pharmacological sciences · 2021
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Kristopher K AbneySchool of Graduate Studies and Research , Meharry Medical College , Nashville , Tennessee 37208 , United States.
Michael BubserVanderbilt Department of Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States.
Yu DuVanderbilt Department of Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States.
Krystian A KozekVanderbilt Department of Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States.
Thomas M BridgesVanderbilt Center for Neuroscience Drug Discovery , Nashville , Tennessee 37232 , United States.
Craig W LinsdleyVanderbilt Department of Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States.ORCID 0000-0003-0168-1445
J Scott DanielsPrecera Biosciences , Franklin , Tennessee 37067 , United States.
Ryan D MorrisonPrecera Biosciences , Franklin , Tennessee 37067 , United States.
Kevin WickmanDepartment of Pharmacology , University of Minnesota , Minneapolis , Minnesota 55455 , United States.
Corey R HopkinsDepartment of Pharmaceutical Sciences, College of Pharmacy , University of Nebraska Medical Center , Omaha , Nebraska 68198 , United States.ORCID 0000-0003-4958-1697
Carrie K JonesVanderbilt Department of Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States.
C David WeaverVanderbilt Department of Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States.ORCID 0000-0002-6886-1195
Vanderbilt University · USMeharry Medical College · USNebraska Medical Center · USUniversity of Minnesota · US

Funding

THE MEHARRY RISE INITIATIVER25GM059994 · NIGMS · MEHARRY MEDICAL COLLEGE · PI MOTLEY-JOHNSON, EVANGELINE D · 1999 to 2021
$23.0M
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel ActivatorR01MH107399 · NIMH · VANDERBILT UNIVERSITY · PI HOPKINS, COREY R., WEAVER, C DAVID · 2015 to 2017
$1.6M
Fluorescent and Luminescent Kinetic Imaging Plate ReaderS10OD021734 · OD · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2016 to 2016
$671k
NIGMS NIH HHS R25 GM059994NIH HHS S10 OD021734NIMH NIH HHS R01 MH107399
6 · The paper itself

Abstract

G protein-gated inwardly rectifying potassium (GIRK) channels are potassium-selective ion channels. As their name suggests, GIRK channels are effectors of G

Indexed as

AnalgesicsAnimalsDisease Models, AnimalDose-Response Relationship, DrugDrug Therapy, CombinationFormaldehydeG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHEK293 CellsHot TemperatureHumansMaleMice, Inbred C57BLMorphinePainPhenylurea CompoundsPyrazolesAnalgesicsFormaldehydeG Protein-Coupled Inwardly-Rectifying Potassium ChannelsMorphinePhenylurea CompoundsPyrazolesVU0466551activatoranalgesiaformalin assayGIRKhot platemorphine

Identifiers

PMID30474955
PMCPMC6765219
OpenAlexW2903337332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.